Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Underweight | Research

Abdominal fat and muscle distributions in different stages of colorectal cancer

Authors: Jun Han, Xinyang Liu, Min Tang, Fan Yang, Zuoyou Ding, Guohao Wu

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

The purpose of this study is to explore the difference of abdominal fat and muscle composition, especially subcutaneous and visceral adipose tissue, in different stages of colorectal cancer (CRC).

Materials and methods

Patients were divided into 4 groups: healthy controls (patients without colorectal polyp), polyp group (patients with colorectal polyp), cancer group (CRC patients without cachexia), and cachexia group (CRC patients with cachexia). Skeletal muscle (SM), subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and intermuscular adipose tissue (IMAT) were assessed at the third lumbar level on computed tomography images obtained within 30 days before colonoscopy or surgery. One-way ANOVA and linear regression were used to analyze the difference of abdominal fat and muscle composition in different stages of CRC.

Results

A total of 1513 patients were divided into healthy controls, polyp group, cancer group, and cachexia group, respectively. In the development of CRC from normal mucosa to polyp and cancer, the VAT area of the polyp group was significantly higher than that of the healthy controls both in male (156.32 ± 69.71 cm2 vs. 141.97 ± 79.40 cm2, P = 0.014) and female patients (108.69 ± 53.95 cm2 vs. 96.28 ± 46.70 cm2, P = 0.044). However, no significant differences were observed of SAT area between polyp group and healthy controls in both sexes. SAT area decreased significantly in the male cancer group compared with the polyp group (111.16 ± 46.98 cm2 vs. 126.40 ± 43.52 cm2, P = 0.001), while no such change was observed in female patients. When compared with healthy controls, the SM, IMAT, SAT, and VAT areas of cachexia group was significantly decreased by 9.25 cm2 (95% CI: 5.39–13.11 cm2, P < 0.001), 1.93 cm2 (95% CI: 0.54–3.32 cm2, P = 0.001), 28.84 cm2 (95% CI: 17.84–39.83 cm2, P < 0.001), and 31.31 cm2 (95% CI: 18.12–44.51 cm2, P < 0.001) after adjusting for age and gender.

Conclusion

Abdominal fat and muscle composition, especially SAT and VAT, was differently distributed in different stages of CRC. It is necessary to pay attention to the different roles of subcutaneous and visceral adipose tissue in the development of CRC.
Appendix
Available only for authorised users
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefPubMed
2.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRefPubMed
3.
Greuter MJ, Demirel E, Lew JB, Berkhof J, Xu XM, Canfell K, et al. Long-term impact of the dutch Colorectal Cancer Screening Program on Cancer incidence and mortality-model-based exploration of the serrated pathway. Cancer Epidemiol Biomarkers Prev. 2016;25:135–44.CrossRefPubMed
4.
5.
6.
Nagata N, Sakamoto K, Arai T, Niikura R, Shimbo T, Shinozaki M, et al. Visceral abdominal fat measured by computed tomography is associated with an increased risk of colorectal adenoma. Int J Cancer. 2014;135:2273–81.CrossRefPubMed
7.
Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11:11–8.CrossRefPubMed
8.
Vijay J, Gauthier MF, Biswell RL, Louiselle DA, Johnston JJ, Cheung WA, et al. Single-cell analysis of human adipose tissue identifies depot and disease specific cell types. Nat Metab. 2020;2:97–109.CrossRefPubMed
9.
10.
Vazzana N, Riondino S, Toto V, Guadagni F, Roselli M, Davi G, et al. Obesity-driven inflammation and colorectal cancer. Curr Med Chem. 2012;19:5837–53.CrossRefPubMed
11.
Greco F, Mallio CA, Grippo R, Messina L, Vallese S, Rabitti C, et al. Increased visceral adipose tissue in male patients with non-clear cell renal cell carcinoma. Radiol Med. 2020;125:538–43.CrossRefPubMed
12.
Im JP, Kim D, Chung SJ, Jin EH, Han YM, Park MJ, et al. Visceral obesity as a risk factor for colorectal adenoma occurrence in surveillance colonoscopy. Gastrointest Endosc. 2018;88:119–127e114.CrossRefPubMed
13.
Gomez-Perez SL, Chaudhry V, Mar W, Patel B, Fantuzzi G, Freels S, et al. Impact of abdominal adipose depots and race on risk for Colorectal Cancer: a case-control study. Nutr Cancer. 2017;69:573–9.CrossRefPubMedPubMedCentral
14.
von Hessen L, Roumet M, Maurer MH, Lange N, Reeves H, Dufour JF, et al. High subcutaneous adipose tissue density correlates negatively with survival in patients with hepatocellular carcinoma. Liver Int. 2021;41:828–36.CrossRef
15.
Han J, Tang M, Lu C, Shen L, She J, Wu G. Subcutaneous, but not visceral, adipose tissue as a marker for prognosis in gastric cancer patients with cachexia. Clin Nutr. 2021;40:5156–61.CrossRefPubMed
16.
Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol (1985) 2000, 89:104–110.
17.
18.
Yim JE, Heshka S, Albu J, Heymsfield S, Kuznia P, Harris T, et al. Intermuscular adipose tissue rivals visceral adipose tissue in independent associations with cardiovascular risk. Int J Obes (Lond). 2007;31:1400–5.CrossRefPubMed
19.
van Vugt JL, Levolger S, Gharbharan A, Koek M, Niessen WJ, Burger JW, et al. A comparative study of software programmes for cross-sectional skeletal muscle and adipose tissue measurements on abdominal computed tomography scans of rectal cancer patients. J Cachexia Sarcopenia Muscle. 2017;8:285–97.CrossRefPubMed
20.
Yip C, Dinkel C, Mahajan A, Siddique M, Cook GJ, Goh V. Imaging abdominal fat and muscle composition @@@@@@ in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging. 2015;6:489–97.CrossRefPubMedPubMedCentral
21.
Faron A, Luetkens JA, Schmeel FC, Kuetting DLR, Thomas D, Sprinkart AM. Quantification of fat and skeletal muscle tissue at abdominal computed tomography: associations between single-slice measurements and total compartment volumes. Abdom Radiol (NY). 2019;44:1907–16.CrossRefPubMed
22.
Murray TE, Williams D, Lee MJ. Osteoporosis, obesity, and sarcopenia on abdominal CT: a review of epidemiology, diagnostic criteria, and management strategies for the reporting radiologist. Abdom Radiol (NY). 2017;42:2376–86.CrossRefPubMed
23.
Chartrand G, Cheng PM, Vorontsov E, Drozdzal M, Turcotte S, Pal CJ, et al. Deep learning: a primer for radiologists. Radiographics. 2017;37:2113–31.CrossRefPubMed
24.
Dabiri S, Popuri K, Ma C, Chow V, Feliciano EMC, Caan BJ, et al. Deep learning method for localization and segmentation of abdominal CT. Comput Med Imaging Graph. 2020;85:101776.CrossRefPubMedPubMedCentral
25.
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95.CrossRefPubMed
26.
Zhang S, Tan S, Jiang Y, Xi Q, Meng Q, Zhuang Q, et al. Sarcopenia as a predictor of poor surgical and oncologic outcomes after abdominal surgery for digestive tract cancer: a prospective cohort study. Clin Nutr. 2019;38:2881–8.CrossRefPubMed
27.
Fukushima H, Takemura K, Suzuki H, Koga F. Impact of Sarcopenia as a Prognostic Biomarker of Bladder Cancer.Int J Mol Sci2018,19.
28.
Ryan AM, Sullivan ES. Impact of musculoskeletal degradation on cancer outcomes and strategies for management in clinical practice. Proc Nutr Soc. 2021;80:73–91.CrossRefPubMed
29.
Kobayashi T, Kawai H, Nakano O, Abe S, Kamimura H, Sakamaki A, et al. Prognostic value of subcutaneous adipose tissue volume in hepatocellular carcinoma treated with transcatheter intra-arterial therapy. Cancer Manag Res. 2018;10:2231–9.CrossRefPubMedPubMedCentral
30.
Pai PC, Chuang CC, Chuang WC, Tsang NM, Tseng CK, Chen KH, et al. Pretreatment subcutaneous adipose tissue predicts the outcomes of patients with head and neck cancer receiving definitive radiation and chemoradiation in Taiwan. Cancer Med. 2018;7:1630–41.CrossRefPubMedPubMedCentral
31.
32.
Moon JM, Im JP, Kim D, Han YM, Soh H, Song JH, et al. Increasing changes in visceral adiposity is associated with higher risk for colorectal adenoma: multilevel analysis in a prospective cohort. J Gastroenterol Hepatol. 2021;36:1836–42.CrossRefPubMed
33.
Hu H, Cai Y, Huang J, Zhang J, Deng Y. Visceral adipose tissue and the risk of colorectal adenomas: a meta-analysis of observational studies. Eur J Cancer Prev. 2015;24:462–9.CrossRefPubMed
34.
Jung IS, Shin CM, Park SJ, Park YS, Yoon H, Jo HJ, et al. Association of visceral adiposity and insulin resistance with colorectal adenoma and colorectal cancer. Intest Res. 2019;17:404–12.CrossRefPubMed
35.
Akay S, Urkan M, Balyemez U, Ersen M, Tasar M. Is visceral obesity associated with colorectal cancer? The first volumetric study using all CT slices. Diagn Interv Radiol. 2019;25:338–45.CrossRefPubMedPubMedCentral
36.
37.
Ebadi M, Baracos VE, Bathe OF, Robinson LE, Mazurak VC. Loss of visceral adipose tissue precedes subcutaneous adipose tissue and associates with n-6 fatty acid content. Clin Nutr. 2016;35:1347–53.CrossRefPubMed
38.
Dolly A, Dumas JF, Servais S. Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know? J Cachexia Sarcopenia Muscle. 2020;11:1413–28.CrossRefPubMedPubMedCentral
39.
Schmidt SF, Rohm M, Herzig S, Berriel Diaz M. Cancer Cachexia: more than skeletal muscle wasting. Trends Cancer. 2018;4:849–60.CrossRefPubMed
Metadata
Title
Abdominal fat and muscle distributions in different stages of colorectal cancer
Authors
Jun Han
Xinyang Liu
Min Tang
Fan Yang
Zuoyou Ding
Guohao Wu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10736-2

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Chidamide enhances cytotoxicity of doxorubicin by promoting autophagy and apoptosis in breast cancer

Research

Evaluating patient reported outcomes and experiences in a novel proton beam clinic – challenges, activities, and outcomes of the ProtonCare project

Research

ARHGAP39 is a prognostic biomarker involved in immune infiltration in breast cancer

Research article

Controlling Nutritional Status (CONUT) score is a prognostic marker in III-IV NSCLC patients receiving first-line chemotherapy

Research

Study of some potential biomarkers in Egyptian hepatitis C virus patients in relation to liver disease progression and HCC

Research

Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits